Tat as a transcriptional activator and a potential therapeutic target for HIV-1.
Gatignol
A
A
U529 INSERM, Institut Cochin de Génétique Moléculaire, Paris, France.
Jeang
K T
KT
D000123:Acetyltransferases / Q000378:metabolism; D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D056906:Cyclin T; D016213:Cyclins / Q000502:physiology; D015696:Gene Products, tat / Q000037:antagonists & inhibitors / Q000502:physiology*; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology; D051548:Histone Acetyltransferases; D006801:Humans; D016601:RNA-Binding Proteins / Q000502:physiology; D029701:Saccharomyces cerevisiae Proteins; D015534:Trans-Activators / Q000502:physiology*; D015533:Transcriptional Activation; D014779:Virus Replication; D054322:tat Gene Products, Human Immunodeficiency Virus; D000099253:Trans-Activation Responsive RNA-Binding Protein
D000123:Acetyltransferases; D056906:Cyclin T; D016213:Cyclins; D015696:Gene Products, tat; D051548:Histone Acetyltransferases; D016601:RNA-Binding Proteins; D029701:Saccharomyces cerevisiae Proteins; D015534:Trans-Activators; D054322:tat Gene Products, Human Immunodeficiency Virus; D000099253:Trans-Activation Responsive RNA-Binding Protein; C503684:CCNT1 protein, human